

HOGAN & HARTSON
L.L.P.

1 4 2 5 ' 0 3 AUG - 4 P 3 4 4

DAVID M. FOX
PARTNER
(202) 637-5678
DMFOX@HHLAW.COM

COLUMBIA SQUARE
555 THIRTEENTH STREET, NW
WASHINGTON, DC 20004-1109
TEL (202) 637-5600
FAX (202) 637-5910
WWW.HHLAW.COM

August 4, 2003

BY FACSIMILE AND HAND DELIVERY

Dockets Management Branch (HFA-305)

Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Re: Docket Number 2003P-0321

Dear Sir or Madam:

We are writing to provide the Food and Drug Administration with notice of our intent to respond to the comments that have been submitted in opposition to the petition submitted by ICN/Ribapharm on July 16, 2003. We have recently received the comments submitted by Three Rivers Pharmaceuticals, LLP (Three Rivers) and have been informed by Dockets Management that the comments submitted by the Hepatitis C Action & Advocacy Coalition (HAAC) will not be available until later this week.

Based on our review of the Three Rivers comments, there are clearly issues that require our response. We intend to submit our reply to these comments as expeditiously as possible.

Respectfully submitted,

David M. Fox

David M. Fox
Hogan & Hartson LLP
555 Thirteenth Street, NW
Washington, DC 20004
(202) 637-5678

2003P-0321

LET 1